Journal article icon

Journal article

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

Abstract:

Chemoresistance is mediated, in part, by the inhibition of apoptosis in tumor cells. Survivin is an antiapoptotic protein that blocks chemotherapy-induced apoptosis. To investigate whether blocking survivin expression enhances docetaxel-induced apoptosis in patients with non–small-cell lung cancer (NSCLC), we compared the antitumor activity of the survivin inhibitor LY2181308 plus docetaxel with docetaxel alone. We used change in tumor size (CTS) as a primary endpoint to assess its use in ear...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1097/jto.0000000000000285

Authors


Publisher:
Elsevier
Journal:
Journal of Thoracic Oncology More from this journal
Issue:
11
Publication date:
2014-11-01
DOI:
EISSN:
1556-1380
ISSN:
1556-0864
Pmid:
25436803
Language:
English
Keywords:
Pubs id:
pubs:491976
UUID:
uuid:972bf8ff-94e3-44ca-bcca-5e71ef8bb743
Local pid:
pubs:491976
Source identifiers:
491976
Deposit date:
2018-03-05

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP